Between 2016 and mid-2018, Jacob Gottlieb has been conspicuously missing from the healthcare investment world. After the demise of Visium Asset Management where he was the founder and chief investment officer, he took some time to clear off the operations of the firm. Now, he is back with another investment form known as Altium Capital. Gottlieb has used the past two years working on refunding funds to investors while at the same time investing in philanthropic work. He has given out donations to organizations that conduct activities that are close to his heart. Most of the organizations he has been supporting are local organizations in New York, and his mode of contribution has mainly been through financial assistance.
Altium Capital is a healthcare investment firm that has been established based on the strengths of Gottlieb as a funds manager. He is not wasting any time since he started since already he has made various investments. In the first five months of operations, the firm had recorded a 7.37 percent return on its growth fund. With such numbers coming out in just five months of operation, it means that Gottlieb is up to something major. The pace of growth of the new company will be tremendous.
Altium Capital has invested in three main companies. The first one is Oramed Pharmaceuticals where he has 5.6 percent stake. This company is coming up with an oral drug that will replace the insulin injections for diabetes patients. Gottlieb sees this as a great opportunity for patients to access low-cost treatment and one that does not cause infections. Another company he has invested in is Amarin, a firm that is developing drugs to boost cardiovascular health. The last company is Oragenics, a firm that is developing antibiotics against infectious diseases.
The strategic investments made by Gottlieb indicate that he ready to amass a large portfolio. He has brought together a team of professionals in the financial and healthcare sectors to help him with the management of the new firm. Most of the professionals he has brought together are successful hedge fund managers and medical experts.
Altium offices are located in New York City where he has surrounded himself with other prominent healthcare investment firms. Jacob Gottlieb is currently sharing office space with a fellow titan in the industry Stuart Weisbrod with whom they worked at Merlin Group. With the two working together, there will be a huge impact on the healthcare industry.
Altium Capital has been in operation since June 2018. In the first five months of operation, the growth report indicates that Gottlieb is doing very well. The Altium Growth Fund has recorded 7.37 percent returns in this period.
Altium Capital is looking for investment opportunities in companies that are coming up with innovative ways of boosting services and medications in the world. Their focus is on the global industry and not just the United States. A good example is Oramed Pharmaceuticals that is based in Jerusalem.
One of the factors that have contributed to the growth of this firm is the management. Gottlieb is keen on recruiting professionals who will conduct themselves professionally. The team members are highly successful experts on financial and medical sector and therefore they can spot great investment opportunities. Most of the investment decisions are made based on risk-reward opportunities after conducting a thorough fundamental analysis of the sector. Jacob Gottlieb holds the positions of the founder, managing partner and chief executive officer. Mark Gottlieb is the chief operating officer.
Jacob holds a degree in economics from Brown University and a medical degree from New York University Medical School. He has combined skills in both to achieve success as an investor.